Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
148553-50-8
Molecular formula
C8H17NO2
Molecular weight
159.23 g/mol
Drug class
Gabapentinoidligand of the alpha-2-delta subunit of voltage-gated calcium channels
Mechanism of action
Binds with high affinity to the alpha-2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system, reducing calcium influx and release of excitatory neurotransmitters. It is not a direct GABA receptor agonist.
Indications / reported uses
Neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia and spinal cord injury in adults, according to product label
Adjunctive treatment of partial-onset seizures in eligible patients
Fibromyalgia in adults under the US product indication; use for other pain syndromes may be off-label and jurisdiction-specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Pregabalin Environmental Risk Assessment (ERA) (the Pregabalin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.